MRI can detect endometrial cancer and is considered the imaging method of choice for evaluating it before surgery. However, MRI is not typically the first test used to find endometrial cancer. Its greatest strength lies in determining how far the cancer has spread within the uterus, which directly shapes treatment decisions and predicts outcomes.
How MRI Fits Into Diagnosis
Most endometrial cancers are initially discovered through a biopsy, usually after a woman reports abnormal bleeding and an ultrasound shows a thickened uterine lining. Once cancer is confirmed by biopsy, MRI enters the picture as the best tool for answering the critical next questions: How deep has the cancer grown into the uterine wall? Has it reached the cervix? Are nearby lymph nodes involved?
This process is called staging, and it determines everything from the type of surgery you’ll need to whether additional treatments like radiation are recommended. The 2023 FIGO staging system, the international standard for classifying endometrial cancer, relies heavily on MRI findings to distinguish between stages. Updated guidelines from the European Society of Urogenital Radiology emphasize standardized MRI protocols specifically to improve staging accuracy and reduce variability between institutions.
What MRI Can See
MRI excels at soft tissue contrast, which makes it uniquely suited to the uterus. It can distinguish between the inner lining (endometrium), the muscular wall (myometrium), and the outer surface of the uterus in ways that CT scans and ultrasound cannot match. Cancerous tissue looks different from healthy tissue on multiple MRI sequences, particularly when the tumor restricts the normal movement of water molecules. This restricted movement shows up as a bright signal on specific imaging sequences and helps radiologists tell cancer apart from benign conditions like polyps, fibroids, and thickened endometrial tissue.
The measurement values from these sequences are significantly lower in endometrial cancer compared to normal endometrium or benign growths, giving radiologists a quantitative tool on top of what they can see visually.
Accuracy for Myometrial Invasion
The depth of cancer invasion into the muscular wall of the uterus is one of the most important factors in treatment planning. Cancers that penetrate more than halfway through the wall carry a higher risk of lymph node spread and a worse prognosis. MRI’s overall accuracy for determining invasion depth is approximately 86%, with a sensitivity of 72% and specificity of 91% for detecting deep invasion.
Those numbers mean MRI is quite reliable when it says the cancer has not deeply invaded (it’s right about 91% of the time), but it misses some cases of deep invasion, catching roughly 7 out of 10. This matters because the cases it misses may be understaged, potentially affecting surgical planning.
Accuracy drops noticeably in women who have fibroids or adenomyosis. In one study, the presence of these conditions reduced sensitivity for detecting deep invasion from 94% down to 57%. Fibroids distort the boundary between the endometrium and myometrium, making it harder for radiologists to judge how far cancer has penetrated.
Staging Beyond the Uterus
MRI’s performance varies depending on what it’s being asked to detect. For cervical involvement, sensitivity is about 58% with a specificity of 96%. This means MRI rarely says the cervix is involved when it isn’t, but it misses cervical spread in roughly 4 out of 10 cases where it exists.
For lymph node metastasis, MRI has a well-known limitation. Its sensitivity for detecting cancerous pelvic lymph nodes is only about 36%, because both MRI and CT rely primarily on node size to flag problems. Cancer-containing lymph nodes that haven’t yet enlarged look identical to normal nodes on imaging. Some advanced techniques that track how quickly contrast dye flows through nodes can improve detection, but they come with trade-offs in specificity.
Vaginal and ovarian spread are also difficult to catch. MRI detected vaginal involvement in only about a third of confirmed cases, and ovarian metastasis in fewer than 1 in 5.
MRI vs. Transvaginal Ultrasound
Since transvaginal ultrasound is cheaper, faster, and more widely available, researchers have compared it head-to-head with MRI for assessing myometrial invasion. A systematic review and meta-analysis found that MRI had slightly better sensitivity (83% vs. 75%) for detecting deep invasion, while ultrasound had a slight edge in specificity (86% vs. 82%). The difference between the two was not statistically significant.
In practice, many centers use ultrasound as the initial assessment and reserve MRI for cases where ultrasound results are unclear, the cancer appears aggressive on biopsy, or detailed surgical planning is needed. MRI provides a more comprehensive view of the entire pelvis in a single exam, which is particularly valuable when there’s concern about spread beyond the uterus.
What Can Cause Misleading Results
Several conditions can trip up even experienced radiologists reading a pelvic MRI for endometrial cancer. The most common pitfalls include:
- Fibroids: Multiple fibroids disrupt the normal boundary between the endometrial lining and the muscular wall, making invasion depth difficult to judge.
- Adenomyosis: This condition, where endometrial tissue grows into the muscular wall, creates signal changes that can mimic cancer invasion.
- Blood clots in the uterine cavity: Accumulated blood can distend the cavity and obscure the anatomical detail needed for accurate assessment.
- Uterine atrophy: In older women, a naturally thinned muscular wall makes it harder to measure invasion depth. When there’s very little wall to invade, even shallow cancer can appear to have penetrated deeply.
- Previous curettage: Scarring from prior procedures can alter the appearance of the uterine lining and complicate interpretation.
When multiple pitfalls are present in the same patient, the risk of misinterpretation increases substantially.
How Contrast Dye Helps
Most pelvic MRIs for endometrial cancer include an injection of gadolinium-based contrast dye. The contrast highlights differences in blood supply between cancerous and normal tissue. One of its most valuable roles is revealing a thin layer of enhancement between the endometrium and the myometrium. When this layer appears intact, it indicates the cancer has not invaded the muscular wall, which is especially useful for younger women who want to preserve fertility.
Dynamic contrast imaging, where multiple rapid image sets are captured as the dye flows through tissue over 4 to 6 minutes, provides more information than a single post-contrast snapshot. However, a single-phase approach (one set of images taken about 4 to 5 minutes after injection) is sometimes used as a faster alternative.
What to Expect During the Scan
A pelvic MRI for endometrial cancer evaluation typically requires fasting for 4 hours beforehand. You can take your usual medications with small sips of water. Some centers may administer a medication to reduce bowel movement during the scan, which improves image quality by minimizing motion artifacts. In certain cases, ultrasound gel may be placed via a small catheter in the rectum or vagina to help distinguish pelvic structures more clearly.
The contrast-enhanced portion of the scan takes roughly 4 to 6 minutes, though the entire appointment is longer when you factor in positioning, non-contrast sequences, and preparation. The full scan typically runs 30 to 45 minutes in the machine. You’ll lie still on your back while the scanner captures hundreds of images, sometimes exceeding 600 individual image slices in a dynamic study.
The Bigger Picture
MRI is not a screening tool for endometrial cancer and won’t replace a biopsy for confirming the diagnosis. Its real value comes after cancer is already known to exist, where it provides the most detailed map of how far disease has spread within the pelvis. This information directly shapes whether a surgeon performs a simple or radical hysterectomy, whether lymph nodes need to be removed, and whether additional therapy is warranted. The 2023 FIGO staging update has further strengthened MRI’s role by integrating imaging findings with molecular tumor characteristics, allowing for more personalized risk assessment and treatment planning.